Global and United States Paroxysmal Nocturnal Hemoglobinuria Drug Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Paroxysmal Nocturnal Hemoglobinuria Drug Market Report & Forecast 2024-2034
Market Analysis and InsightsGlobal and United States Paroxysmal Nocturnal Hemoglobinuria Drug Market
This report focuses on global and United States Paroxysmal Nocturnal Hemoglobinuria Drug market, also covers the segmentation data of other regions in regional level and county level.
The global Paroxysmal Nocturnal Hemoglobinuria Drug revenue was US$ 3200 million in 2022 and is forecast to a readjusted size of US$ 7528.3 million by 2029 with a CAGR of 13.0% during the forecast period (2024-2034).
In United States the Paroxysmal Nocturnal Hemoglobinuria Drug revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of Paroxysmal Nocturnal Hemoglobinuria Drug include Apellis Pharmaceuticals, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc, CinnaGen Co, Ra Pharmaceuticals Inc, Amgen Inc, Achillion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc and F. Hoffmann-La Roche Ltd, etc. The global five biggest players hold a share of % in 2022.
Global Paroxysmal Nocturnal Hemoglobinuria Drug Scope and Market Size
Paroxysmal Nocturnal Hemoglobinuria Drug market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Paroxysmal Nocturnal Hemoglobinuria Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For United States market, this report focuses on the Paroxysmal Nocturnal Hemoglobinuria Drug market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.
Apellis Pharmaceuticals
Alexion Pharmaceuticals Inc
Akari Therapeutics Plc
CinnaGen Co
Ra Pharmaceuticals Inc
Amgen Inc
Achillion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Novartis AG
Regeneron Pharmaceuticals Inc
BIOCAD
Samsung Bioepis
Amyndas Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
LGM Pharma.
Lannett
NorthStar Rx LLC
Abbott
Par Pharmaceutical
Segment by Type
Eculizumab
Ravulizumab
Others
Clinic
Hospital
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Paroxysmal Nocturnal Hemoglobinuria Drug definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Paroxysmal Nocturnal Hemoglobinuria Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Paroxysmal Nocturnal Hemoglobinuria Drug sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
This report focuses on global and United States Paroxysmal Nocturnal Hemoglobinuria Drug market, also covers the segmentation data of other regions in regional level and county level.
The global Paroxysmal Nocturnal Hemoglobinuria Drug revenue was US$ 3200 million in 2022 and is forecast to a readjusted size of US$ 7528.3 million by 2029 with a CAGR of 13.0% during the forecast period (2024-2034).
In United States the Paroxysmal Nocturnal Hemoglobinuria Drug revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of Paroxysmal Nocturnal Hemoglobinuria Drug include Apellis Pharmaceuticals, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc, CinnaGen Co, Ra Pharmaceuticals Inc, Amgen Inc, Achillion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc and F. Hoffmann-La Roche Ltd, etc. The global five biggest players hold a share of % in 2022.
Global Paroxysmal Nocturnal Hemoglobinuria Drug Scope and Market Size
Paroxysmal Nocturnal Hemoglobinuria Drug market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Paroxysmal Nocturnal Hemoglobinuria Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For United States market, this report focuses on the Paroxysmal Nocturnal Hemoglobinuria Drug market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.
By Company
Apellis Pharmaceuticals
Alexion Pharmaceuticals Inc
Akari Therapeutics Plc
CinnaGen Co
Ra Pharmaceuticals Inc
Amgen Inc
Achillion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Novartis AG
Regeneron Pharmaceuticals Inc
BIOCAD
Samsung Bioepis
Amyndas Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
LGM Pharma.
Lannett
NorthStar Rx LLC
Abbott
Par Pharmaceutical
Segment by Type
Eculizumab
Ravulizumab
Others
Segment by Application
Clinic
Hospital
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Paroxysmal Nocturnal Hemoglobinuria Drug definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Paroxysmal Nocturnal Hemoglobinuria Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Paroxysmal Nocturnal Hemoglobinuria Drug sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices